Abbott 研究发现 2 型糖尿病患者同时使用 GLP-1 药物和 FreeStyle Libre 技术可显着降低 HbA1c 水平 2.4%。 Abbott study finds Type 2 Diabetes patients using GLP-1 medicines and FreeStyle Libre technology together significantly reduce HbA1c levels by 2.4%.
雅培实验室的研究表明，同时使用 GLP-1 药物和 FreeStyle Libre 技术可显着改善 2 型糖尿病患者的 HbA1c 水平，与单独使用 GLP-1 时的 1.7% 相比，降低了 2.4%。 Abbott Lab's study shows that using GLP-1 medicines and FreeStyle Libre technology together significantly improved Type 2 Diabetes patients' HbA1c levels, reducing them by 2.4% compared to 1.7% when using GLP-1 alone. 该研究结果在第十七届糖尿病先进技术与治疗国际会议上公布。 The study findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes. 雅培 (Abbott) 股票目前在纽约证券交易所上涨 0.63%。 Abbott's stock is currently up 0.63% on the New York Stock Exchange.